Literature DB >> 18663283

Nephrogenic systemic fibrosis.

Neha Nainani1, Mandip Panesar.   

Abstract

Nephrogenic systemic fibrosis is a recently diagnosed disease that occurs in patients with chronic kidney disease and acute renal failure. The patients develop skin thickening and fibrosis which is usually symmetrical, and typically of the upper and lower extremities. In some cases the progression is rapid leading to joint contractures confining the patient to a wheelchair. Systemic involvement may occur, leading to cardiomyopathy, pulmonary fibrosis, pulmonary hypertension, diaphragmatic paralysis and in severe cases death. The pathophysiology of the disease still remains unclear, but recent studies have demonstrated gadolinium deposits in tissues of patients diagnosed with nephrogenic systemic fibrosis. The prevalence of nephrogenic systemic fibrosis after exposure to gadolinium has been reported to be up to 12% in CKD stage 5 patients after a single exposure. No single treatment has been shown to be effective, although there are some patients shown to have improvement of their clinical symptoms with regaining of renal function especially after transplantation. In this article we review the current literature of this disease. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18663283     DOI: 10.1159/000149628

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  Advanced MRI of articular cartilage.

Authors:  Hillary J Braun; Garry E Gold
Journal:  Imaging Med       Date:  2011-10

Review 2.  MR imaging of articular cartilage physiology.

Authors:  Jung-Ah Choi; Garry E Gold
Journal:  Magn Reson Imaging Clin N Am       Date:  2011-05       Impact factor: 2.266

Review 3.  A Review of Clinical Translation of Inorganic Nanoparticles.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

Review 4.  Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease.

Authors:  Eugene Y H Chan; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-25       Impact factor: 3.714

5.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

6.  Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.

Authors:  Samuel Dambreville; Arlene B Chapman; Vicente E Torres; Bernard F King; Ashley K Wallin; David H Frakes; Ajit P Yoganathan; Sameera R Wijayawardana; Kirk Easley; Kyongtae T Bae; Marijn E Brummer
Journal:  Magn Reson Med       Date:  2010-04       Impact factor: 4.668

7.  In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis.

Authors:  Christi M Terry; Li Li; Huan Li; Ilya Zhuplatov; Donald K Blumenthal; Seong-Eun Kim; Shawn C Owen; Eugene G Kholmovski; Kirk D Fowers; Ramesh Rathi; Alfred K Cheung
Journal:  J Control Release       Date:  2012-03-17       Impact factor: 9.776

8.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04

Review 9.  Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.

Authors:  Sandra Lange; Wioletta Mędrzycka-Dąbrowska; Katarzyna Zorena; Sebastian Dąbrowski; Daniel Ślęzak; Anna Malecka-Dubiela; Przemysław Rutkowski
Journal:  Int J Environ Res Public Health       Date:  2021-03-15       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.